MX2014008194A - Cefovecina util en el tratamiento de la enfermedad de lyme. - Google Patents

Cefovecina util en el tratamiento de la enfermedad de lyme.

Info

Publication number
MX2014008194A
MX2014008194A MX2014008194A MX2014008194A MX2014008194A MX 2014008194 A MX2014008194 A MX 2014008194A MX 2014008194 A MX2014008194 A MX 2014008194A MX 2014008194 A MX2014008194 A MX 2014008194A MX 2014008194 A MX2014008194 A MX 2014008194A
Authority
MX
Mexico
Prior art keywords
lyme disease
treating lyme
treating
cefovecin
animals
Prior art date
Application number
MX2014008194A
Other languages
English (en)
Inventor
Patrick F M Meeus
Christopher L Haber
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of MX2014008194A publication Critical patent/MX2014008194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un procedimiento de tratamiento de la enfermedad de Lyme y/o de una infección por Borrelia en animales, que comprende administración a un animal que lo necesita de una cantidad terapéuticamente efectiva de cefovecina.
MX2014008194A 2012-01-03 2012-12-20 Cefovecina util en el tratamiento de la enfermedad de lyme. MX2014008194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582742P 2012-01-03 2012-01-03
PCT/US2012/070753 WO2013103531A1 (en) 2012-01-03 2012-12-20 A method for treating lyme disease

Publications (1)

Publication Number Publication Date
MX2014008194A true MX2014008194A (es) 2015-03-19

Family

ID=47459202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008194A MX2014008194A (es) 2012-01-03 2012-12-20 Cefovecina util en el tratamiento de la enfermedad de lyme.

Country Status (10)

Country Link
US (1) US9265771B2 (es)
EP (1) EP2800570A1 (es)
JP (1) JP2013139443A (es)
AR (1) AR093734A1 (es)
AU (1) AU2012363652A1 (es)
BR (1) BR112014016575A8 (es)
CA (1) CA2860574C (es)
MX (1) MX2014008194A (es)
WO (1) WO2013103531A1 (es)
ZA (1) ZA201405451B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034984A1 (en) * 2015-08-21 2017-03-02 The Johns Hopkins University Identification of additional anti-persister activity against borrelia burgdorferi from an fda drug library

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142731A2 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid

Also Published As

Publication number Publication date
BR112014016575A2 (pt) 2017-06-13
US9265771B2 (en) 2016-02-23
AR093734A1 (es) 2015-06-24
BR112014016575A8 (pt) 2017-07-04
AU2012363652A1 (en) 2014-07-24
CA2860574C (en) 2017-01-03
ZA201405451B (en) 2015-12-23
US20140343003A1 (en) 2014-11-20
CA2860574A1 (en) 2013-07-11
JP2013139443A (ja) 2013-07-18
WO2013103531A1 (en) 2013-07-11
EP2800570A1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
UA115231C2 (uk) Сполуки імідазопіролідинонів
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
PL2870913T3 (pl) Urządzenie do pobierania, przechowywania i/albo obróbki krwi lub innych substancji pochodzenia ludzkiego lub zwierzęcego, i do stosowania preparatów krwiopochodnych lub innych preparatów biologicznych
FR3001121B1 (fr) Pince de traitement d'un tissu corporel et necessaire de traitement associe
PT2848097T (pt) Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa
FR3006582B1 (fr) Dispositif de traitement d'un tissu corporel et necessaire de traitement associe
IN2015DN00450A (es)
EA201590115A1 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
EP2898064A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF LESION AND TISSUE DISEASE
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
EA201491875A1 (ru) Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
MX2022015141A (es) Composiciones y metodos de uso de un compuesto de control de inapetencia.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
GB2515440A (en) Vesicular formulations
MX2015007862A (es) Derivado de amida del acido cinamico.
MX2014008194A (es) Cefovecina util en el tratamiento de la enfermedad de lyme.
BR112015002726A2 (pt) combinação, uso de uma combinação, composição farmacêutica, uso de uma composição farmacêutica, kit, e método de tratamento de uma infecção ou doença relacionada a tal infecção em humanos ou animais.
BR112015002727A2 (pt) combinação, uso de uma combinação, composição farmacêutica, uso de uma composição farmacêutica, kit, e, método para tratamento de uma infecção ou doença relacionada a tal infecção em humanos ou animais.
BR112014006593A2 (pt) dispositivo médico para inserção no corpo humano
PL2574295T3 (pl) Urządzenie do usuwania kleszczy i innych ciał obcych ze skóry człowieka lub zwierzęcia